Additional file 1 of Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease

Additional file 1: Table S1. Summary of replication cohort characteristics. Table S2. Clinical and immunoassay metadata for all 88 cases. Table S3. Raw PRM quantified peptide peak area before normalization. Table S4. Normalized peptide peak areas. Table S5. Normalized Protein Quantification. Table S6. Normalized Protein Quantification (Regressed for age and sex). Table S7. Differential Expression Analysis (ANOVA). Table S8. Correlation of all proteins quantified in the TMT discovery cohort with ELISA-measured t-tau, pTau, Aβ, and Aβ/Tau ratio. Table S9. ROC analysis.

补充材料1：表S1 重复队列特征汇总；表S2 全部88例病例的临床及免疫测定元数据；表S3 归一化前经平行反应监测（Parallel Reaction Monitoring, PRM）定量的肽段峰面积原始数据；表S4 归一化后的肽段峰面积；表S5 归一化蛋白质定量结果；表S6 针对年龄与性别进行回归校正后的归一化蛋白质定量结果；表S7 差异表达分析（ANOVA，方差分析）；表S8 串联质量标签（Tandem Mass Tag, TMT）标记的发现队列中定量的全部蛋白质与酶联免疫吸附测定（Enzyme-Linked Immunosorbent Assay, ELISA）所得总tau蛋白（t-tau）、磷酸化tau蛋白（pTau）、β淀粉样蛋白（Aβ）及Aβ/Tau比值的相关性分析；表S9 受试者工作特征（Receiver Operating Characteristic, ROC）分析